Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupImmunodeficienciesDiseaseAntibody Deficiency, PrimarySubgroupICD10MeSHPrimary Immunodeficiency DiseasesSequenceRHUH(800/1600/2400)/SCIgG(10/20/30), prim. Antibody deficiency, C1 (PID1726) -|- RHUH2400/SCIgG30, C2+ (PID1731)ChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceHuman immunoglobulin, subcutaneousRecombinant Human HyaluronidaseSupportive substanceHuman immunoglobulin, subcutaneousRecombinant Human HyaluronidaseSupportive substanceHuman immunoglobulin, subcutaneousRecombinant Human HyaluronidaseSupportive substanceHuman immunoglobulin, subcutaneousRecombinant Human HyaluronidaseNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentiondisease controlsupportiveRisksAllergic ReactionHeadachePain only studiesPublicationAuthorWasserman RLDiseasePrimäre HypogammaglobulinämieOriginAllergy/Immunology Research Center of North Texas, Dallas, USAProtocols in Revision 2 protocols foundRecombinant Human Hyaluronidase (800/1600/2400) / Human Immunoglobulin G (10/20/30), subcutaneous, Primary Antibody Deficiency, Cycle 1 (PID1726 V1.1)Recombinant Human Hyaluronidase, 2400 / Human Immunoglobulin G 30, subcutaneous, Primary Antibody Deficiency, Cycle 2+ (PID1731 V1.1)
